Lamictal olarak da bilinen Lamotrigin, n\u00f6bet \u00f6nleyici bir ila\u00e7t\u0131r. FDA taraf\u0131ndan onaylanm\u0131\u015ft\u0131r<\/a> for treatment of epilepsy and bipolar disorder. Lamotrigine is used alone or with other medicines to treat seizures in patients two years and older. It may also be used as maintenance treatment in patients with bipolar disorder to help delay the occurrence of mood episodes such as depression, mania, or hypomania. Stopping lamotrigine without first talking to a prescriber can lead to uncontrolled seizures, or new or worsening mental health problems. Lamotrigine has been approved and on the market for 24 years, and is available under the brand name Lamictal and as generics.<\/p>\n Lamictal was first sold in the United States in 1994 and is manufactured by GlaxoSmithKline. It is a sodium channel blocker that helps by suppressing the excitatory neurotransmitters in the central nervous system.\u00a0 Lamictal is available both as an oral tablet and in a chewable form and is metabolized by the liver.\u00a0 Between 2005 and 2015, there were more than 900,000,000 prescriptions for the drug in the United States.\u00a0\u00a0 Lamictal has been one of GlaxoSmithKline\u2019s best-selling drugs of all time and sales between March 2007 and March 2008 exceeded $2 billion.<\/p>\n <\/p>\n Hastan\u0131n duygudurum bozukluklar\u0131na yard\u0131mc\u0131 olman\u0131n yan\u0131 s\u0131ra, Lamictal ayr\u0131ca kullan\u0131m i\u00e7in onayland\u0131<\/a> antiepileptik bir ila\u00e7 olarak.<\/p>\n 2008 y\u0131l\u0131nda yaz\u0131lm\u0131\u015f bir makale<\/a> by Nasser et al. reviewed evidence from Lamictal trials that were unpublished, and it concludes that lamotrigine has “very limited, if any, efficacy in the treatment of acute bipolar depression”. A 2008 makalesi, Calabrese ve di\u011ferleri.<\/a> ayn\u0131 verilerin \u00e7o\u011funu inceledi ve be\u015f plasebo kontroll\u00fc \u00e7al\u0131\u015fmada, lamotrijinin bipolar depresyon tedavisinde plasebodan \u00f6nemli \u00f6l\u00e7\u00fcde farkl\u0131 olmad\u0131\u011f\u0131n\u0131 buldu.<\/p>\n <\/p>\n Lamiktal kullan\u0131m\u0131ndan kaynaklanan bir yan etki olarak \u00e7ok ciddi ve ya\u015fam\u0131 tehdit eden bir ba\u011f\u0131\u015f\u0131kl\u0131k sistemi reaksiyonu tan\u0131mlanm\u0131\u015ft\u0131r. Bu ba\u011f\u0131\u015f\u0131kl\u0131k sistemi reaksiyonu, ba\u011f\u0131\u015f\u0131kl\u0131k sisteminin v\u00fccudun dokular\u0131na ve organlar\u0131na zarar vermesine neden olan HLH (hemofagositik lenfohistiyositoz anlam\u0131na gelir) olarak adland\u0131r\u0131l\u0131r. Bu, v\u00fccutta ciddi iltihaba neden olabilir ve \u00f6zellikle reaksiyon h\u0131zl\u0131 bir \u015fekilde te\u015fhis edilip tedavi edilmezse hastaneye yat\u0131\u015fa ve \u00f6l\u00fcme yol a\u00e7abilir. HLH tipik olarak, genellikle 101 \u00b0 F'den daha y\u00fcksek olan kal\u0131c\u0131 bir ate\u015f olarak ortaya \u00e7\u0131kar ve karaci\u011fer, b\u00f6brekler, beyin ve akci\u011ferler gibi v\u00fccuttaki kan h\u00fccreleri ve organlarda ciddi sorunlara yol a\u00e7abilir.<\/p>\n <\/p>\n G\u0131da ve \u0130la\u00e7 \u0130daresine g\u00f6re, bir hastada a\u015fa\u011f\u0131daki sekiz belirti veya semptomdan en az be\u015fi varsa, HLH te\u015fhisi konulabilir:<\/p>\n Hastalar veya bak\u0131c\u0131lar\u0131, lamotrijin al\u0131rken herhangi bir HLH semptomu ya\u015farlarsa, sa\u011fl\u0131k uzmanlar\u0131yla hemen ileti\u015fime ge\u00e7melidir. HLH, tedaviye ba\u015flad\u0131ktan sonraki g\u00fcnler ila haftalar i\u00e7inde ortaya \u00e7\u0131kabilir. HLH'yi te\u015fhis etmek i\u00e7in fizik muayene ve spesifik laboratuvar kan testleri ve di\u011fer de\u011ferlendirmeler kullan\u0131l\u0131r. HLH belirtileri ve semptomlar\u0131 bunlarla s\u0131n\u0131rl\u0131 olmamak \u00fczere \u015funlar\u0131 i\u00e7erir:<\/p>\n <\/p>\n <\/p>\n 25 Nisan 2018 tarihinde, FDA uyar\u0131 yay\u0131nlad\u0131<\/a> that Lamictal can cause this rare, but very serious reaction.\u00a0Because of the association with HLH, the FDA required the manufacturer of Lamictal to add a new warning about the risk of HLH to the prescribing information in the lamotrigine drug labels. \u00a0The FDA also issued an alert to healthcare professionals stating they should be aware that prompt recognition and early treatment is important for improving HLH outcomes and decreasing mortality. Diagnosis is often complicated because early signs and symptoms such as fever and rash are not specific. HLH may also be confused with other serious immune-related adverse reactions such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).<\/p>\n In the 24 years since lamotrigine\u2019s 1994 approval, the FDA identified many cases worldwide of confirmed or suspected HLH associated with the medicine in children and adults. This number includes only reports submitted to FDA and found in the medical literature, so there are likely additional cases about which the FDA is unaware. The FDA determined that \u201cthere was reasonable evidence that lamotrigine was the cause of HLH\u201d in these cases based on the timing of events and the order in which they occurred. The patients in these cases required hospitalization and received drug and other medical treatments, with one patient dying.<\/p>\n <\/p>\n Lamictal, ilac\u0131n tehlikeli oldu\u011fu hakk\u0131nda hi\u00e7bir fikri olmayan binlerce insan\u0131 yaralad\u0131. Lamictal kullan\u0131rken size veya sevdi\u011finiz birine HLH te\u015fhisi konduysa, Napoli Shkolnik PLLC ile ileti\u015fime ge\u00e7in ve deneyimli bir ki\u015fiyle konu\u015fun. ila\u00e7 dava avukat\u0131<\/a> New York'ta. \u0130hmal durumlar\u0131nda \u00f6nceden yasal \u00fccret alm\u0131yoruz.<\/p>","protected":false},"excerpt":{"rendered":" ARTIK LAM\u0130KTAL VAKALARI KABUL ETM\u0130YORUZ Arka plan Lamictal olarak da bilinen Lamotrigin, epilepsi ve bipolar bozuklu\u011fun tedavisi i\u00e7in FDA taraf\u0131ndan onaylanan bir anti-n\u00f6bet ilac\u0131d\u0131r\u2026.<\/p>","protected":false},"featured_media":0,"menu_order":137,"template":"","practiceareas_category":[743],"class_list":["post-5934","practiceareas","type-practiceareas","status-publish","hentry","practiceareas_category-pharmaceutical-litigation"],"acf":[],"_links":{"self":[{"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/practiceareas\/5934","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/practiceareas"}],"about":[{"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/types\/practiceareas"}],"version-history":[{"count":0,"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/practiceareas\/5934\/revisions"}],"wp:attachment":[{"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/media?parent=5934"}],"wp:term":[{"taxonomy":"practiceareas_category","embeddable":true,"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/practiceareas_category?post=5934"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Bir antiepileptik ila\u00e7 olarak lamiktal<\/h3>\n
Lamiktal ve HLH<\/h3>\n
HLH hakk\u0131nda bilgiler<\/h2>\n
\n
\n
Lamotrijin (Lamictal) hakk\u0131nda ger\u00e7ekler<\/h2>\n
\n
\n
G\u00fcvenlik i\u00e7in FDA Eylemi<\/h3>\n
Bir Avukatla Konu\u015fun<\/h3>\n